BMO Capital analyst John McNulty downgrades Venator Materials (NYSE:VNTR) from Market Perform to Underperform and announces $0.6 price target.
Ironwood’s Constipation Drug Shows Efficacy In Pediatric Patients
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.
